<?xml version="1.0" encoding="UTF-8"?>
<p id="Par265">Effects of the therapy results in:
 <list list-type="bullet">
  <list-item>
   <p id="Par266">The frequency of HIV-1-related CNS diseases has been reduced through
    <list list-type="bullet">
     <list-item>
      <p id="Par267">the reduction of both viral load in the blood</p>
     </list-item>
     <list-item>
      <p id="Par268">the reduced continuous penetration of virus into the brain (Tardieu 
       <xref ref-type="bibr" rid="CR1320">1999</xref>)
      </p>
     </list-item>
    </list>
   </p>
  </list-item>
  <list-item>
   <p id="Par269">HIV-positive patients live longer.</p>
  </list-item>
  <list-item>
   <p id="Par270">The median survival
    <list list-type="bullet">
     <list-item>
      <p id="Par271">following AIDS increased from 19.6 months in 1993–1995 to 39.6 months for those diagnosed in 1996–2000</p>
     </list-item>
     <list-item>
      <p id="Par272">following ADC increased from 11.9 months in 1993–1995 to 48.2 in 1996–2000.</p>
     </list-item>
    </list>
   </p>
  </list-item>
  <list-item>
   <p id="Par273">The proportion of patients with AIDS dementia complex (ADC) increased from 5.2% in 1993–1995 to 6.8% in 1996–2000.</p>
  </list-item>
 </list>
</p>
